Ketamine was applied to treat breast cancer, and the results showed that ketamine could increase lipid ROS, malondialdehyde (MDA), and Fe2+ in breast cancer cells, inhibiting the expression of the ferroptosis factor GPX4 by attenuating KAT5 on the GPX4 promoter region and reducing histone H3 lysine 27 acetylation (H3K27ac) and the enrichment of RNA polymer II (RNA pol II), ultimately leading to breast cancer cell ferroptosis (Li et al., 2021b). This evidence concerns the gene KAT5 and breast carcinoma.